A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs ASP 9853 (Primary) ; Docetaxel; Paclitaxel
- Indications Cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 01 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Nov 2012 New trial record